38.87
price up icon2.99%   1.13
after-market Handel nachbörslich: 38.75 -0.12 -0.31%
loading

Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten

pulisher
May 31, 2025

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

May 31, 2025
pulisher
May 29, 2025

SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm - FinancialContent

May 29, 2025
pulisher
May 29, 2025

Intellia Plunges in Latest Example of Gene Therapy Troubles - Bloomberg

May 29, 2025
pulisher
May 29, 2025

July 11th Options Now Available For Sarepta Therapeutics (SRPT) - Nasdaq

May 29, 2025
pulisher
May 29, 2025

We Think The Compensation For Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Looks About Right - simplywall.st

May 29, 2025
pulisher
May 27, 2025

Oppenheimer to Host Important Meeting for SRPT Investors | SRPT Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Gene Therapy Death Worsens Picture for an Already Troubled Field - Barron's

May 27, 2025
pulisher
May 27, 2025

Was Jim Cramer Right About Sarepta Therapeutics Inc. (SRPT)? - Insider Monkey

May 27, 2025
pulisher
May 27, 2025

FDA halts Rocket Pharma's gene therapy trial as patient dies - Reuters

May 27, 2025
pulisher
May 27, 2025

Was Jim Cramer Right About These 11 Stocks? - Insider Monkey

May 27, 2025
pulisher
May 27, 2025

D. E. Shaw & Co. Inc. Sells 11,389,239 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World

May 27, 2025
pulisher
May 27, 2025

Sarepta Therapeutics’ SWOT analysis: gene therapy leader faces growth challenges - Investing.com

May 27, 2025
pulisher
May 26, 2025

Will Moderna's Rally Continue? - Forbes

May 26, 2025
pulisher
May 22, 2025

SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm | FinancialContent - FinancialContent

May 22, 2025
pulisher
May 22, 2025

FDA advisers pan Pfizer’s PARP drug; Sarepta to resume Duchenne study - BioPharma Dive

May 22, 2025
pulisher
May 22, 2025

SRPT: HC Wainwright & Co. Reiterates Neutral Rating on Sarepta Therapeutics | SRPT Stock News - GuruFocus

May 22, 2025
pulisher
May 21, 2025

Sarepta (SRPT) Rises as UK Greenlights Elevidys Study | SRPT Sto - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVID - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Sarepta Therapeutics (NasdaqGS:SRPT) Continues Phase 3 Study of ELEVIDYS Gene Therapy in Duchenne - Yahoo Finance

May 21, 2025
pulisher
May 21, 2025

Sarepta (SRPT) Rises as UK Greenlights Elevidys Study | SRPT Stock News - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Sarepta Therapeutics (SRPT) Rallies After UK Lifts Clinical Hold on Elevidys Trials - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Sarepta Therapeutics Stock Gains After U.K. Lets Elevidys Study Continue - MarketWatch

May 21, 2025
pulisher
May 21, 2025

Sarepta, Roche get U.K. feedback to continue dosing in Elevidys' Duchenne trial - Seeking Alpha

May 21, 2025
pulisher
May 21, 2025

Sarepta (SRPT) Gains UK Approval to Continue Gene Therapy Study - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Sarepta Therapeutics Says Dosing to Continue in UK Trial of Duchenne Muscular Dystrophy Treatment - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy | SRPT Stock News - GuruFocus

May 21, 2025
pulisher
May 20, 2025

Sarepta Therapeutics (SRPT) Price Target Lowered by JP Morgan | - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Sarepta Therapeutics (SRPT) Price Target Lowered by JP Morgan | SRPT Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Assessing Sarepta Therapeutics: Insights From 30 Financial Analysts - Benzinga

May 20, 2025
pulisher
May 20, 2025

Sarepta Therapeutics (SRPT) Price Target Reduced by JPMorgan | S - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Sarepta Therapeutics (SRPT) Price Target Reduced by JPMorgan | SRPT Stock News - GuruFocus

May 20, 2025
pulisher
May 19, 2025

SRPT Q1 Earnings Call: Sarepta Adjusts Guidance After Safety Event and Administrative Delays - Yahoo Finance

May 19, 2025
pulisher
May 19, 2025

Sarepta reports outcomes from trial of Duchenne muscular dystrophy therapy - Yahoo Finance

May 19, 2025
pulisher
May 17, 2025

Sarepta reports promising ELEVIDYS study results for Duchenne By Investing.com - Investing.com Nigeria

May 17, 2025
pulisher
May 17, 2025

Sarepta Therapeutics Shares New Protein Expression and Safety Re - GuruFocus

May 17, 2025
pulisher
May 17, 2025

Sarepta Therapeutics Presents Data at the American Society of Ge - GuruFocus

May 17, 2025
pulisher
May 16, 2025

Sarepta seeks to expand Duchenne gene therapy Elevidys use to toddlers - Endpoints News

May 16, 2025
pulisher
May 16, 2025

Sarepta (SRPT) Reports Promising Results from ELEVIDYS Trial in Young Patients | SRPT Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Sarepta (SRPT) Shows Promising Results for Duchenne Gene Therapy - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Sarepta Reports New Elevidys Data from Two Separate Studies in Duchenne Muscular Dystrophy - marketscreener.com

May 16, 2025
pulisher
May 16, 2025

Sarepta (SRPT) Shows Promising Results for Duchenne Gene Therapy | SRPT Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Sarepta reports promising ELEVIDYS study results for Duchenne - Investing.com Australia

May 16, 2025
pulisher
May 16, 2025

Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysi - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Sarepta Seeks to Strengthen Elevidys’ Case With Data in Older Kids - BioSpace

May 16, 2025
pulisher
May 16, 2025

Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment - itemonline.com

May 16, 2025
pulisher
May 16, 2025

Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2 - Business Wire

May 16, 2025
pulisher
May 15, 2025

Nucleic Acid Therapeutics Market Trends, Size & Growth Forecast - openPR.com

May 15, 2025
pulisher
May 15, 2025

2 Healthcare Stocks to Keep an Eye On and 1 to Ignore - Yahoo Finance

May 15, 2025
pulisher
May 14, 2025

Sarepta at BofA Conference: Navigating Challenges and Growth - Investing.com

May 14, 2025
pulisher
May 14, 2025

Bearish: Analysts Just Cut Their Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Revenue and EPS estimates - Yahoo Finance

May 14, 2025
$1.16
price up icon 0.87%
$31.13
price down icon 0.19%
$576.61
price down icon 1.37%
$303.77
price down icon 0.76%
$4.5807
price down icon 0.41%
$487.86
price down icon 0.60%
Kapitalisierung:     |  Volumen (24h):